Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

Overview

• Fennec Pharmaceuticals, which reported Thursday, said net product sales reached $15.1 million in the first quarter, up 73% year over year, marking a sixth straight quarter of growth and positive operating cash flow.
• Project Ignite expanded the company’s reach from roughly 1,300 to more than 5,000 target prescribers, and the Fennec HEARS support program hit an 80% conversion benchmark that helped more patients complete therapy.
• PEDMARK is used to reduce permanent hearing loss from the chemotherapy drug cisplatin in children with localized, non‑metastatic solid tumors, which makes wider prescriber adoption central to patient access.
• Management no longer expects a previously anticipated milestone from Germany and forecasts a temporary cash dip in Q2 due to collections timing, with a return to positive cash flow projected later in 2026.
• Academic interest is growing through investigator‑initiated studies in adolescent, young adult, and adult cancers, and partner Norgine plans European launches in 2026 that the company expects to broaden uptake.